Compare Crispr Therapeutics AG (CRSP) vs iShares China Large-Cap ETF (FXI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs iShares China Large-Cap ETF — how do they compare? Crispr Therapeutics AG trades at $52.75 (market cap $4.88B), while iShares China Large-Cap ETF trades at $34.19 (market cap $3.86B). The key difference: Crispr Therapeutics AG is the larger of the two by market cap, and iShares China Large-Cap ETF is more actively traded (16,323,837 versus 2,861,747). Which is the better fit depends on your goals — on Pluang, investors hold Crispr Therapeutics AG for 77 Days and iShares China Large-Cap ETF for 149 Days on average.
| CRSP | FXI | |
|---|---|---|
Market Cap | $4.88B | $3.86B |
Volume | 2,861,747 | 16,323,837 |
Sector | Health | — |
52-Week High | $74.92 | $41.08 |
52-Week Low | $44.34 | $31.59 |
Typical Hold Time | 77 Days | 149 Days |
Enterprise Value | $3.30B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $52.35, down 3.06% with bearish technical signals. The company shows negative profitability metrics including -$581.6M net income and -4,101.26% net margin for 2025, though revenue is expected to grow from $0 to $11M in 2026. Recent news highlights upcoming clinical data presentations and CASGEVY's commercial potential, with analyst consensus leaning bullish despite fundamental challenges.
The outlook remains speculative with significant cash burn but promising pipeline catalysts. Investment opportunity lies in gene-editing breakthroughs and CASGEVY adoption, while risks include sustained losses, clinical trial outcomes, and competitive pressure. Wall Street maintains a $67.83 price target, suggesting 30% upside if execution improves.
FXI (iShares China Large-Cap ETF) trades at $34.30, up 2.63% on the day, but technical indicators signal a bearish trend with 17 sell signals versus 1 buy. The ETF faces headwinds from China's economic challenges and geopolitical tensions, though some analysts highlight its attractive valuation at half the S&P 500's P/E ratio. Recent news focuses on U.S.-China relations and export dynamics.
The outlook remains cautious due to China's industrial overcapacity and weak domestic consumption. While valuation appears compelling, political risks and technical weakness suggest limited near-term upside. Investors should weigh the discount against ongoing macroeconomic pressures in China.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About iShares China Large-Cap ETF
The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. The index designed to measure the performance of the largest companies in the Chinese equity market that trade on the Stock Exchange of Hong Kong and are available to international investors. The fund is non-diversified.
Read more on FXI →
